In generalized cases, bullous pemphigoid (BP) requires treatment with oral systemic corticosteroids, l mg/kg per day, prednisone or prednisolone. Despite oral steroids, BP is not controlled in about 30% of patients treated with prednisolone metasulfobenzoate (PO-MS), 1 mg/kg per day.1,2 Prednisolone is the active molecule accounting for the anti-inflammatory activity in vivo after oral intake of prednisone or PO-MS. Some cases of clinical resistance in patients treated for inflammatory diseases have been observed following the administration of PO-MS, which were reversed using prednisone in the same mole-per-liter dose. Pharmacokinetic studies in healthy subjects showed higher availability of prednisolone after administration of prednisone than after PO-MS because of better intestinal absorption of prednisone.3- 5 The aim of this retrospective study was to determine if prednisone if more efficacious than PO-MS for the initial control of BP.
Lebrun-Vignes B, Roujeau J, Bernard P, Delaporte E, Joly P, Prost C, Vaillant L, Herson S, Chosidow O. Prednisone Is More Effective Than Prednisolone Metasulfobenzoate in the Treatment of Bullous Pemphigoid. Arch Dermatol. 1999;135(1):89–90. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-1-dlt0199
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.